Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
基本信息
- 批准号:9026653
- 负责人:
- 金额:$ 20.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:4-Aminobutyrate aminotransferaseAgonistBasic ScienceBiological MarkersBlindedCerebrospinal FluidChildClinicalClinical DataClinical PharmacologyClinical ResearchCollaborationsCrossover DesignDataDefectDevelopmentDiseaseDistrict of ColumbiaDoseDrug CompoundingEnvironmentEpilepsyEvaluationEventExtramural ActivitiesFamilyFrequenciesFunctional disorderGABA-B ReceptorGenetic Crossing OverGoalsGrantHealthInformation SystemsIntellectual functioning disabilityInterventionIntervention StudiesLeadLogistic RegressionsMeasuresMedical centerMetabolicMetabolic DiseasesMetabolismModelingMulti-Institutional Clinical TrialMusNational Institute of Neurological Disorders and StrokeNeurocognitiveNormal RangeOutcomeOutcome MeasureOxidoreductaseParticipantPatientsPediatric HospitalsPhasePhenotypePhysiciansPlacebo ControlPlacebosPractical trialProceduresPublicationsQuality of lifeRandomizedReportingResearchResearch PersonnelSGS-742SafetySample SizeSerious Adverse EventSeveritiesSiteSourceSuccinate-semialdehyde dehydrogenase deficiencySystemTaurineTestingTimeTranscranial magnetic stimulationUnited States National Institutes of HealthUniversitiesWashingtonactive methodaldehyde dehydrogenasesaminobutyratearmautism spectrum disorderbasecohortcostdesigneffective therapyefficacy trialexperiencegamma-Aminobutyric Acidinnovationmouse modelneuropsychologicalopen labelphase II trialpreclinical efficacyprimary outcomereceptorsuccesssuccinic semialdehydetrial design
项目摘要
DESCRIPTION (provided by applicant): Succinic semialdehyde dehydrogenase (SSADH) deficiency remains the most prevalent and untreatable disorder of GABA (4-aminobutyrate) metabolism. A placebo-controlled phase II trial of SGS742 (GABA(B) receptor antagonist) in SSADH-deficient patients is proposed, based upon preclinical efficacy findings in the corresponding murine model, which will evaluate safety, tolerability, and change in relevant indicators of SSADH severity in treatment vs. placebo groups. A crossover design will be employed where patients are randomized into an initial six month trial of SGS742 versus placebo. Our project's innovation resides in implementing the first placebo-controlled, blinded trial in this disorder using a rational intervention based upon preclinical efficacy studies in aldh5a1-/- mice. Our single formal hypothesis is that SSADH-deficient patients will have lengthening toward normal values of the cortical silent period (CSP), and return of long interval intracortical inhibition (LICI), during SGS742 intervention as quantified by transcranial magnetic stimulation. Secondary, exploratory outcomes include metabolic biomarkers in cerebrospinal fluid (GABA, GHB), neuropsychological evaluation, and safety. Aim 1 will compare the effect of SGS742 v. PBO on TMS levels as the primary outcome, relying both on the magnitude of the difference in TMS between the SGS742 and PBO group, as well as the equivalent of a paired t-test to assess the statistical significance level. The same procedure is employed in Aim 2 which evaluates SGS742 effects on biomarker levels, including GABA and GHB, as well as scores on neuropsychological assessments on vs. off SGS742. In Aim 3, we shift to the evaluation of safety. When we evaluate the frequency of adverse or toxic events, our analysis framework will comprise multiple logistic regression models to compare the odds of discrete occurrences such as reported adverse and serious adverse events in those on SGS742 relative to PBO. Appropriate biomarker outcomes, an investigative team with experience in a similar trial of taurine in this patient cohort, a proven, practical trial design, and a broad cohort of recruitable
subjects are features that underscore our potential for success. In the short term, we will formulate a "go/no-go" decision regarding further clinical development of SGS742. The project's long term significance centers on identification of effective treatment for SSADH deficiency and related disorders in which neurocognitive dysfunction correlates with GABAergic systems.
描述(由申请人提供):琥珀酸半醛脱氢酶(SSADH)缺乏症仍然是GABA(4-氨基丁酸)代谢最普遍和不可治疗的疾病。基于相应小鼠模型的临床前疗效发现,提出了SGS742 (GABA(B)受体拮抗剂)在SSADH缺陷患者中的安慰剂对照II期试验,该试验将评估治疗组与安慰剂组的安全性、耐受性以及SSADH严重程度相关指标的变化。将采用交叉设计,将患者随机分为SGS742和安慰剂的初始6个月试验。我们项目的创新之处在于在aldh5a1-/-小鼠的临床前疗效研究的基础上,采用合理的干预措施,在这种疾病中实施了第一个安慰剂对照、盲法试验。我们的单一正式假设是,在经颅磁刺激量化的SGS742干预期间,ssadh缺陷患者的皮质沉默期(CSP)将向正常值延长,并恢复长间隔皮质内抑制(LICI)。其次,探索性结果包括脑脊液中的代谢生物标志物(GABA, GHB),神经心理学评估和安全性。Aim 1将比较SGS742和PBO对TMS水平的影响作为主要结局,依赖于SGS742和PBO组之间TMS差异的大小,以及等效的配对t检验来评估统计显著性水平。Aim 2采用了相同的程序,评估SGS742对生物标志物水平的影响,包括GABA和GHB,以及SGS742对神经心理学评估的评分。在目标3中,我们转向安全性评估。当我们评估不良或毒性事件的频率时,我们的分析框架将包括多个逻辑回归模型,以比较相对于PBO, SGS742患者报告的不良和严重不良事件发生的几率。适当的生物标志物结果,具有在该患者队列中进行牛磺酸类似试验经验的调查团队,经过验证的实用试验设计和广泛的可招募队列
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
K Michael GIBSON其他文献
K Michael GIBSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('K Michael GIBSON', 18)}}的其他基金
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism
琥珀半醛脱氢酶缺乏症 (SSADHD) 的自然史,一种 GABA 代谢的遗传性疾病
- 批准号:
10200868 - 财政年份:2018
- 资助金额:
$ 20.96万 - 项目类别:
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders
Rapalog 疗法治疗遗传性和氨己烯酸诱导的 GABA 代谢紊乱
- 批准号:
9555110 - 财政年份:2017
- 资助金额:
$ 20.96万 - 项目类别:
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders
Rapalog 疗法治疗遗传性和氨己烯酸诱导的 GABA 代谢紊乱
- 批准号:
9918905 - 财政年份:2017
- 资助金额:
$ 20.96万 - 项目类别:
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency
mTOR 信号转导治疗琥珀酸半醛脱氢酶缺乏症
- 批准号:
8769623 - 财政年份:2014
- 资助金额:
$ 20.96万 - 项目类别:
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency
mTOR 信号转导治疗琥珀酸半醛脱氢酶缺乏症
- 批准号:
8848901 - 财政年份:2014
- 资助金额:
$ 20.96万 - 项目类别:
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
- 批准号:
8479999 - 财政年份:2013
- 资助金额:
$ 20.96万 - 项目类别:
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
- 批准号:
8617315 - 财政年份:2013
- 资助金额:
$ 20.96万 - 项目类别:
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria
新颖的治疗方法
- 批准号:
8390456 - 财政年份:2008
- 资助金额:
$ 20.96万 - 项目类别:
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria
新颖的治疗方法
- 批准号:
7938768 - 财政年份:2008
- 资助金额:
$ 20.96万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)